MARGetuximab Or Trastuzumab (MARGOT)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to MacroGenics
Related studies linked through entity extraction aliases.
Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck
- Status
- WITHDRAWN
- Phase
- PHASE2/PHASE3
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
MGD019 DART® Protein in Unresectable/Metastatic Cancer
- Status
- COMPLETED
- Phase
- PHASE1
MGC018 With or Without MGA012 in Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy
- Status
- COMPLETED
- Phase
- PHASE1
MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
MGD009/MGA012 Combination in Relapsed/Refractory Cancer
- Status
- COMPLETED
- Phase
- PHASE1
A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms
- Status
- COMPLETED
- Phase
- PHASE1
Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Safety Study of MGD009 in B7-H3-expressing Tumors
- Status
- TERMINATED
- Phase
- PHASE1
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Phase 1 Study of MGD010 in Healthy Subjects
- Status
- COMPLETED
- Phase
- PHASE1
Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma
- Status
- COMPLETED
- Phase
- PHASE1
Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Tissue Procurement Substudy for Participants in Study CP-MGA271-01
- Status
- TERMINATED
- Phase
- PHASE1